READYFOR
クラウドファンディングとははじめる
ログインログイン・登録
成立

新型コロナウイルス感染症:重症化を抑える新薬の開発に向けた第一歩を

株式会社グライコテクニカ

株式会社グライコテクニカ

新型コロナウイルス感染症:重症化を抑える新薬の開発に向けた第一歩を

支援総額

5,369,000

目標金額 5,000,000円

支援者
204人
募集終了日
2020年12月25日
プロジェクトは成立しました!

終了報告を読む


2020年11月10日 17:50

ENGLISH PAGE 3 (Research Members)

 

Research Members

 

Collaborator: Tatsuro Irimura

Tatsuro Irimura, Ph.D.
Project Professor, Division of Glycobiologics, Intractable Disease Research Center and
Department of Breast Oncology (adjunct), Juntendo University Graduate School of Medicine.
Received his BS (1971), MS (1973), and PhD (1977) from the University of Tokyo.
1974-1980 Research Associate, Division of Chemical Toxicology and Immunochemistry, Faculty
of Pharmaceutical Sciences, The University of Tokyo (Prof. Toshiaki Osawa). Studied on the
glycoconjugate recognition by plant lectins.
1980-1980 Postgraduate Researcher, Department of Developmental and Cell Biology,
University of California, Irvine (Prof. Garth L. Nicolson). Involvement of glycans in melanoma
metastasis.
1980-1988 Assistant Professor, Department of Tumor Biology, The University of Texas M. D.
Anderson Cancer Center. Roles of glycoproteins and glycosaminoglycans in cancer metastasis.
1988-1991 Associate Professor with tenure, Department of Tumor Biology, The University of
Texas M. D. Anderson Cancer Center. Diagnostic and therapeutic applications of mucins and
their glycans to cancer metastasis.
1991-2013 Professor and Head, Laboratory of Cancer Biology and Molecular Immunology,
Graduate School of Pharmaceutical Sciences, The University of Tokyo. Glyco-minded biology of
diseases.
1996-2016 Editor in Chief, Clinical and Experimental Metastasis, Official Journal of the
Metastasis Research Society.
2003-2007 Founder and Boar of Directors, Summit GlycoResearch, Co. Ltd.
2012-2016 Chair of Science Board, Pharmaceutical and Medical Device Agency (PMDA)
2013-2015 Director, Institute for Medical Innovation, St Luke’s International University
2015-2015 Visiting Professor, the University of Texas MD Anderson Cancer Center
2005-present Chair of the Board, Tokyo Foundation for Pharmaceutical Sciences
2013-present Emeritus Professor, The University of Tokyo
2016-present Project Professor, Juntendo University School of Medicine
2016-2020 Chair of the Board of Pharmaceutical Sciences, International Pharmaceutical
Federation

 

●Message

COVID-19, a disease caused by the infection of SARS-CoV-2, is spreading across the world.  Its socioeconomical impacts far more than one can imagine.  Therefore, it is the time for all scientists and engineers to invest their maximum power to invent new technology by which human being overcome this formidable enemy as soon as possible.  Of course, vaccines and drugs such as polymerase inhibitors and anti-spike antibodies are currently the primary focus.  However, the biology of the disease initiated by this virus, which seems to be very complex, should be understood to efficiently deal with the problem.  We do know that, based on our previous endeavor to understand the infection of Ebola virus carbohydrate chains of the viral envelope glycoprotein surrounding its RNA play pivotal roles during the course of infection.  Glycotechnica Company, as one of the leading global companies focusing on glycosylation, decided to tackle Corona viral infection and its aggravation to eventually develop new therapeutic modality to block serious outcomes of COVID-19.  As one of the longstanding collaborators in academia, Glycobiologics laboratory of Juntendo University will support their endeavor by providing knowledges and by instructing experimental skills.  We hope that this collaboration bears many fruits which lead to facilitate better understanding of COVID-19 and development of new, effective and harmless drugs to fight with it.  

 


 

Collaborator: Norio Yamamoto M.D. Ph.D.

Professor of Department of Virology, Division of Host Defense Mechanism, Tokai University School of Medicine
Graduated from the Faculty of Medicine, Tokyo Medical and Dental University in 1996, and on the completion of his doctoral studies at the same medical school in 2000, he qualified as a doctor of medicine, and was appointed as an assistant professor in the Department of Molecular Virology at the university. In 2009, he was appointed as the head of the 5th laboratory at Influenza Virus Research Center, National Institute of Infectious Diseases and conducted research on therapeutic drugs and vaccines for SARS coronavirus and influenza viruses. In 2014, he was appointed as an associate professor in the Department of Infection Control Science at Juntendo University Graduate School of Medicine. Since 2020, he has worked as a professor in the Department of Virology at Tokai University School of Medicine. He specializes in virology, infectious disease treatment and vaccines.

 

Message

COVID-19 has become a global pandemic, infecting more than 42.5 million people with more than 1.14 million deaths (as of 25 October 2020).
A major problem with this infectious disease is that it is more likely to cause severe symptoms for the elderly and those with underlying medical conditions, but the mechanism behind this tendency is not yet well understood.


Based on reports that (1) abnormal activation of immune system is involved in severe cases and (2) the association between ABO blood groups and severity of the symptoms (type A is more likely to lead to severe symptoms while type O less likely to do so), we will be focusing on macrophages, cells which play an important role in the activation of immune system, and sugar chains, including for the ABO blood type, in an attempt to understand the mechanism which causes severe symptoms.


If we can find an answer to the question, ‘What causes severe COVID-19?’, we can use the findings to develop a method to prevent the infection leading to severe symptoms and significantly reduce the health effects of COVID-19. I would like to ask you for your support.

 


 

Sueaki Takabatake Glycotechnica Ltd. Chairman

Joined Toshiba after graduating from the Faculty of Law at Keio University in 1963. After working in thermal power generation, he served as the first representative of the company’s South Africa office, followed by working in the UK as General Manger for Europe and the Middle East region. Based in the U.K., the office acted as an intermediary for projects between Toshiba’s Japanese headquarters and businesses in Africa and the Middle East. On his return to Japan, he was appointed as a non-executive director of Amersham International (U.K.) which became GE Healthcare, the first privatized company in the UK, where he was instrumental in developing life sciences business with Japan.

 

Message

Would you like to take a ride on a cloud?


I first became involved in life sciences business with a British company called Amasham International UK which is now GE Healthcare. The company had produced Nobel Prize-winning scientists and always had its sight set on five to ten years into the future. They led the field from the early stages of the development of PCR, used to diagnose novel coronavirus infections. Although the Japanese biotechnology industry is currently working on developing a variety of diagnostic and therapeutic drugs, I strongly wish that more creative approach to research were undertaken, looking ahead into the future, rather than simply following current trends.

 

New diagnostic agents and therapeutic drugs take long period of time before they are realized. And the reality is that expenditure on research development in the biotechnology industry in Japan is much less than that of the US and Europe, often by an order of magnitude. This research funding for the current infectious disease is needed right now and is vital. We are proceeding with this joint research in the hope that the situation can be improved, even just a little, and hope that the world leading researchers can make use of our expertise in sugar chain analysis technology. We strongly hope that we are able to demonstrate Japanese technological ability in relation to sugar chains and make a contribution by developing a new therapeutic drug for novel coronavirus from the field of sugar chains.


I will be guided by the professors involved in the research and stay out of their way, ensuring that they can work to their full potential. I see this as my last challenge in life and will be hopping on a cloud as a passenger on this crowdfunding endeavour. 

 


 

Sayuki Iijima Ph.D. GlycoTechnica Ltd., Director of GLI Division

Graduated from the Faculty of Science, Ibaraki University, in 1997 and completed studies at the Graduate School of Science at the same university in 1999, and at the Graduate School of Medicine, University of Tsukuba in 2004. In 2004, she joined the then National Institute of Biomedical Innovation as a postdoctoral researcher at the Tsukuba Primate Research Center. In 2010, she joined the Department of Virology and Liver Unit at Nagoya City University Graduate School of Medical Sciences as a postdoctoral researcher. She has been in the current post since 2018.

 

Message

COVID-19 crisis continues to spread throughout the world and there is no end in sight. I sense that people’s stress is mounting as a result of ongoing measures to control the infection. One of the most important issues with the novel coronavirus infection is that of severe cases but there are still many unknowns with the mechanism behind severe COVID-19 and we await clarification. Sugar chains are closely connected with viral infections and were used as a basis for analyzing various types of viruses in the past. We would like to make an effort to make use of our company’s technology to combat COVID-19 crisis. 

 


 

Masao Yamada Ph.D. GlycoTechnica Ltd., Honorary Chief Scientific Adviser 

Received PhD from Department of Electrical and Electronic Engineering at Graduate School of Engineering, Nagoya University. 1983~2002: worked at Electronic Device Business Unit, Fujitsu Ltd. and between 2004~2009, he worked at Moritex Inc. (Director/Head of Glycomics Laboratory). He was a director at GP Bioscience Ltd. between 2009 and 2013 before taking up the current post. Other positions include Consulting Associate Professor at Stanford University and Visiting Professor at Nagoya University.

 

Message

The new coronavirus has become a massive pandemic once in 100 years, and its economic impact has led to a recession beyond the Leaman shock. What to do without fighting now? Researchers around the world are working hard to elucidate the pathogenesis of COVID-19 and develop therapeutic drugs and vaccines. In order for small players like our company to win such a race, we have to focus our resources to just one point and push it forward vigorously. Now is the time to bring the glycan and lectin technologies we have cultivated over 10 years as an unique technology originated in Japan up to the surface, and contribute it to health and prosperity of humanity.We are encouraging ourselves telling that Now is the time.Our mind in this technology development is documented also in NEDO’s homepage as "Aim the world standard for glycan analysis with a technology from Japan".
https://www.nedo.go.jp/hyoukabu/articles/200808gp/index.html

 


 

▶︎NEXT PAGE 「ENGLISH PAGE 4

 

▶︎Rewards

 

▶︎How to pledge support for the project: English Guide

ENGLISH PAGE 2ENGLISH PAGE 4
一覧に戻る

リターン

3,000


alt

3,000円支援コース

・サンクスメール
・研究内容の結果報告書(電子メールにて送付いたします)

支援者
78人
在庫数
制限なし
発送完了予定月
2021年12月

10,000


alt

10,000円支援コース

・サンクスメール
・研究内容の結果報告書(電子メールにて送付いたします)
・ホームページにお名前記載(希望制)

支援者
82人
在庫数
制限なし
発送完了予定月
2021年12月

30,000


alt

30,000円支援コース

・サンクスメール
・研究内容の結果報告書(電子メールにて送付いたします)
・ホームページにお名前記載(希望制)

支援者
20人
在庫数
制限なし
発送完了予定月
2021年12月

50,000


alt

50,000円支援コース

・サンクスメール
・研究内容の結果報告書(電子メールにて送付いたします)
・ホームページにお名前記載(希望制)
・レクチンマイクロアレイの見本

※「レクチンマイクロアレイの見本」の画像はページ未尾に記載しております。

支援者
10人
在庫数
制限なし
発送完了予定月
2021年12月

100,000


alt

100,000円支援コース

・サンクスメール
・研究内容の結果報告書(電子メールにて送付いたします)
・ホームページにお名前記載(希望制)
・レクチンマイクロアレイの見本

※「レクチンマイクロアレイの見本」の画像はページ未尾に記載しております。

支援者
16人
在庫数
制限なし
発送完了予定月
2021年12月

300,000


alt

300,000円支援コース

・サンクスメール
・研究内容の結果報告書(電子メールにて送付いたします)
・ホームページにお名前記載(希望制)
・レクチンマイクロアレイの見本
・(株)グライコテクニカのラボ見学ツアー
・プロジェクト内容についてオンライン説明会

※見学ツアーは2021年3〜5月頃を予定しており、日時の詳細は別途メールにてご相談させていただきます。現地までの交通費は支援者様ご負担とさせていただきます。また、新型コロナウイルス感染症の影響でオンランツアーもしくは別のイベントになる可能性がございます。場所は、神奈川県の本社を予定しております。状況によっては、つくば研究所に変更の可能性もございます。
※オンライン説明会は、2021年11〜12月頃を予定して、日時の詳細は別途メールにてご相談させていただきます。
※「レクチンマイクロアレイの見本」の画像はページ未尾に記載しております。

支援者
3人
在庫数
制限なし
発送完了予定月
2021年12月

500,000


alt

500,000円支援コース

・サンクスメール
・研究内容の結果報告書(電子メールにて送付いたします)
・ホームページにお名前記載(希望制)
・レクチンマイクロアレイの見本
・(株)グライコテクニカのラボ見学ツアー
・プロジェクト内容についてオンライン説明会

※見学ツアーは2021年3〜5月頃を予定しており、日時の詳細は別途メールにてご相談させていただきます。現地までの交通費は支援者様ご負担とさせていただきます。また、新型コロナウイルス感染症の影響でオンランツアーもしくは別のイベントになる可能性がございます。場所は、神奈川県の本社を予定しております。状況によっては、つくば研究所に変更の可能性もございます。
※オンライン説明会は、2021年11〜12月頃を予定して、日時の詳細は別途メールにてご相談させていただきます。
※「レクチンマイクロアレイの見本」の画像はページ未尾に記載しております。

支援者
1人
在庫数
制限なし
発送完了予定月
2021年12月

1,000,000


alt

1,000,000円支援コース

・サンクスメール
・研究内容の結果報告書(電子メールにて送付いたします)
・ホームページにお名前記載(希望制)
・レクチンマイクロアレイの見本
・(株)グライコテクニカのラボ見学ツアー
・プロジェクト内容についてオンライン説明会

※見学ツアーは2021年3〜5月頃を予定しており、日時の詳細は別途メールにてご相談させていただきます。現地までの交通費は支援者様ご負担とさせていただきます。また、新型コロナウイルス感染症の影響でオンランツアーもしくは別のイベントになる可能性がございます。場所は、神奈川県の本社を予定しております。状況によっては、つくば研究所に変更の可能性もございます。
※オンライン説明会は、2021年11〜12月頃を予定して、日時の詳細は別途メールにてご相談させていただきます。
※「レクチンマイクロアレイの見本」の画像はページ未尾に記載しております。

支援者
0人
在庫数
制限なし
発送完了予定月
2021年12月
プロジェクトの相談をする